TableĀ 3

Meta-analysis of overall AEs

OutcomeInterventionComparatorStudiesNFixed effects
RR (95% CI)p ValueI2 (%)
Any AENicergolinePlacebo1014481.05 (0.93 to 1.20)*0.420
Any AENicergolineActive agents42921.19 (0.71 to 2.01)*0.515
Any AENicergolineErgot derivatives22001.22 (0.63 to 2.34)*0.5619
Any SAENicergolinePlacebo24820.85 (0.50 to 1.45)0.5435
AnxietyNicergolinePlacebo24820.59 (0.39 to 0.88)0.010
DiarrhoeaNicergolinePlacebo21880.85 (0.24 to 3.05)0.80
DiarrhoeaNicergolineErgot derivatives22000.99 (0.14 to 6.92)0.990
DizzinessNicergolinePlacebo32600.63 (0.15 to 2.57)0.510
DizzinessNicergolineActive agents21161.00 (0.18 to 5.58)*1.00
DrowsinessNicergolinePlacebo24420.34 (0.05 to 2.12)0.240
FatigueNicergolinePlacebo23780.71 (0.14 to 3.53)0.6818
FatigueNicergolineActive agents32601.24 (0.35 to 4.47)*0.740
FatigueNicergolineErgot derivatives22001.79 (0.40 to 7.98)*0.450
Gastric upsetNicergolinePlacebo610370.94 (0.58 to 1.52)0.80
Hot flushesNicergolineAll comparisons34703.65 (0.61 to 21.93)0.160
HeadacheNicergolinePlacebo510041.28 (0.63 to 2.60)*0.240
HypotensionNicergolinePlacebo23781.49 (0.26 to 8.72)*0.660
InsomniaNicergolinePlacebo34981.81 (0.39 to 8.29)*0.450
ItchingNicergolineAll comparisons21083.23 (0.35 to 30.08)*0.30
  • *RR value greater than 1 denotes higher rate of AEs with nicergoline compared with the comparator drug and a value less than 1 denotes vice versa.

  • AE, adverse event; SAE, serious AE.